Buy Jentadueto

Jentadueto

What is Jentadueto?

Jentadueto is a prescription medication used to improve blood-sugar control in adults with type 2 diabetes. It combines two active ingredients:

• Linagliptin - a dipeptidyl peptidase-4 (DPP-4) inhibitor
• Metformin - a biguanide that reduces hepatic glucose production

The fixed-dose combination is available as a pill containing 2.5 mg linagliptin / 500 mg metformin. In the United Kingdom it is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is supplied only with a prescription.

How Jentadueto Works in the Body

• Linagliptin blocks the DPP-4 enzyme, which normally degrades the incretin hormones GLP-1 and GIP. By preserving these hormones, linagliptin increases insulin release after meals and reduces glucagon secretion, helping to lower post-prandial glucose.

• Metformin primarily inhibits hepatic gluconeogenesis, decreasing the amount of glucose released into the bloodstream. It also modestly improves peripheral insulin sensitivity and slows intestinal glucose absorption.

Together, the two agents address different pathways that contribute to hyperglycaemia, providing a complementary approach to glycaemic control.

Conditions Treated by Jentadueto

Jentadueto is approved in the UK for the treatment of type 2 diabetes mellitus when:

• Metformin alone does not achieve adequate glycaemic control, and
• An additional oral agent with a complementary mechanism is required.

It is intended for use in conjunction with diet and exercise as part of a comprehensive diabetes management plan.

Patient Suitability and Contraindications

Who should use Jentadueto?

• Adults with diagnosed type 2 diabetes who are already receiving metformin and need additional glycaemic lowering.
• Patients with a stable renal function (eGFR ≥ 30 mL/min/1.73 m²) and no history of lactic acidosis.

Absolute contraindications

• Known hypersensitivity to linagliptin, metformin, or any excipients.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²).
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis or lactic acidosis.
• Current treatment with any form of alcohol intoxication that predisposes to acidosis.

Relative contraindications / cautions

• Moderate renal impairment (eGFR 30-45 mL/min/1.73 m²) - dose reduction may be needed.
• Hepatic impairment - monitor for signs of lactic acidosis.
• History of pancreatitis.
• Pregnancy or breastfeeding - linagliptin is not recommended; metformin may be used only if the benefit outweighs risk.

Special populations

• Elderly: Assess renal function carefully; start at the lowest dose.
• Renal impairment: Adjust metformin component according to eGFR.
• Pregnancy: Discuss alternatives with a healthcare professional.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or upset stomach (often mild, improves with continued use)
• Diarrhoea or loose stools
• Decreased appetite
• Indigestion or abdominal discomfort

Serious Adverse Events

• Lactic acidosis - rare but life-threatening; emergency medical attention required if symptoms such as confusion, rapid breathing, or severe abdominal pain occur.
• Pancreatitis - severe abdominal pain radiating to the back, nausea, vomiting.
• Severe hypoglycaemia - particularly when combined with sulfonylureas or insulin.

Drug Interactions

• Cimetidine, trimethoprim, or other nephrotoxic agents may increase metformin plasma levels.
• Iodinated contrast agents can precipitate lactic acidosis; pause Jentadueto at least 48 hours before and after contrast administration if renal function is compromised.
• Rifampin modestly reduces linagliptin exposure; monitor glycaemic response.
• Concomitant use of other glucose-lowering drugs (e.g., sulfonylureas, insulin) may increase risk of hypoglycaemia; dose adjustments may be required.

Food and Lifestyle Interactions

• Take with meals to minimise gastrointestinal upset from metformin.
• Alcohol should be limited; excessive intake raises the risk of lactic acidosis.
• No known impairment of driving or use of machinery, but patients should monitor for any dizziness, especially when initiating therapy.

How to Take Jentadueto

• Standard dosing: One tablet containing 2.5 mg linagliptin / 500 mg metformin taken once daily with the first main meal.
• Dose adjustments:
• If glycaemic control is insufficient and renal function permits, the prescriber may increase to a higher strength (e.g., 5 mg/1000 mg) as per the product label.
• For eGFR 30-45 mL/min/1.73 m², the metformin component should be reduced; the prescriber may advise a lower-dose tablet or an alternative regimen.
• Missed dose: Take the missed tablet as soon as remembered if it is still the same day; otherwise skip it and continue with the next scheduled dose. Do not double the dose.
• Overdose: Symptoms may include severe gastrointestinal distress, lethargy, or rapid breathing. Seek emergency medical care; dialysis is the recommended treatment for severe metformin toxicity.
• Discontinuation: Abrupt cessation is generally safe, but when stopping after prolonged use, monitor blood glucose closely to avoid rebound hyperglycaemia.

Monitoring and Follow-Up

• HbA1c: Check every 3 months after initiating or adjusting therapy.
• Renal function: Serum creatinine and eGFR at baseline, then at least annually, or more frequently if risk factors exist.
• Liver enzymes: Periodic monitoring in patients with known hepatic disease.
• Blood glucose: Self-monitoring as directed by the prescribing clinician to detect hypoglycaemia.

Storage and Handling

• Store tablets at room temperature (15-30 °C), away from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use after the expiry date printed on the pack.
• Dispose of any unused tablets according to local pharmacy waste guidelines.

Medication-Specific Glossary

eGFR

Estimated glomerular filtration rate; a calculation used to assess kidney function and guide metformin dosing.

Lactic Acidosis

A rare but serious buildup of lactate in the blood, most often associated with metformin in the setting of impaired renal clearance.

HbA1c

Glycated haemoglobin, a laboratory measure reflecting average blood glucose over the previous 2-3 months; used to monitor diabetes control.

Medical Disclaimer

This article provides educational information about Jentadueto and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.